The consistency and value of immunotherapy
The Drug Discovery World Podcast
Release Date: 09/19/2024
The Drug Discovery World Podcast
The latest episode of the is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In a week that saw a second monoclonal antibody rejected by UK regulator NICE, antibodies have been high on the news agenda. More positively, a new indication for Fasenra was approved in the EU, researchers found an antibody platform could overcome the challenges of treating mutating viruses, and monoclonal antibodies showed promise in lung cancer and immunoglobulin A nephropathy. You can listen...
info_outline How to streamline regulatory approvalThe Drug Discovery World Podcast
This is the latest episode of the free DDW narrated podcast, titled "How to streamline regulatory approval", which covers two articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: and . In the first article, Ken Forman, Senior Director of Product Strategy, IDBS explains how robust digital workflows can reduce errors and time to compile data leading to greater transparency, faster reporting and help biopharmaceutical companies reach regulatory submission faster. In the second article, Craig Caceci, Managing Director at Terebellum, offers guidance to...
info_outline DDW Highlights: 29 October 2024The Drug Discovery World Podcast
The latest episode of the is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With a presidential election just round the corner in the US and a new UK budget on the way, financial support for life sciences is high on the agenda, so the news round-up this week focuses on investment in drug discovery, by private investors, governments and charities. You can listen below, or find The Drug Discovery World Podcast on , and
info_outline The unmet critical need for concussion drug therapiesThe Drug Discovery World Podcast
In theseries, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with CEO of Oxeia, Dr Michael Wyand, where we talk about Oxeia’s work; the unmet critical need for concussion drug therapies; the challenges facing them, including in clinical trials and investment; the potential market for concussion drugs, and more. You can now, and find The Drug Discovery World Podcast on , and
info_outline DDW Highlights: 22 October 2024The Drug Discovery World Podcast
The latest episode of the is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. As we are halfway through , our news highlights this week focus on studies that could advance the treatment of cancer in the future, including a new understanding of cancer drug resistance, and novel therapeutics like radioimmunotherapy, RBM39 degraders and peptide-drug conjugates. You can listen below, or find The Drug Discovery World Podcast on , and
info_outline DDW Highlights: 15 October 2024The Drug Discovery World Podcast
The latest episode of the is now available to listen to. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Recently, the Society for Neuroscience's annual meeting took place, so the headlines have been dominated by the latest discoveries related to the brain and the central nervous system, including significant findings related to GLP-1 agonists and an advanced theory of bipolar disorder. If these are of interest, don’t forget to register for on 24 October. You can listen here, or find The Drug Discovery...
info_outline DDW Highlights: 30 September 2024The Drug Discovery World Podcast
The latest episode of the is now available. The publication of DDW’s latest eBook on immunotherapy has coincided with some interesting developments in this therapy area, particularly monoclonal antibodies, including two new regulatory approvals. You can listen here, or find The Drug Discovery World Podcast on , and
info_outline DDW Highlights: 23 September 2024The Drug Discovery World Podcast
The latest episode of the is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week we have seen a number of developments related to cell therapies, particularly CAR-T cell therapies, beyond their traditional use in haematological malignancies. You can listen below, or find The Drug Discovery World Podcast on , and
info_outline The consistency and value of immunotherapyThe Drug Discovery World Podcast
This is the latest episode of the free DDW narrated podcast, titled “How technology is impacting drug discovery”, which covers two articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: and . The first article looks into why data from a Phase III clinical trial offers promise for patients with a deadly form of brain cancer. The second article shares insight from Dr Shailendra Singh, Founder and CEO of Cellomatics Biosciences.
info_outline DDW Highlights: 17 September 2024The Drug Discovery World Podcast
The latest episode of the is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week, DDW has opened registrations for its webinar ‘’, so our news highlights focus on developments in neuroscience, including a novel drug that has been shown to reduce neuronal death, and a potential disease-modifying treatment for dementia. You can listen below, or find The Drug Discovery World Podcast on , and
info_outlineThis is the latest episode of the free DDW narrated podcast, titled “How technology is impacting drug discovery”, which covers two articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: Immunotherapy offers survival extension for brain tumour patients and The evolution of assays for immuno-oncology research.
The first article looks into why data from a Phase III clinical trial offers promise for patients with a deadly form of brain cancer.
The second article shares insight from Dr Shailendra Singh, Founder and CEO of Cellomatics Biosciences.